Endothelial-to-mesenchymal transition (EndMT) occurs during development and underlies the pathophysiology of multiple diseases. In tumors, unscheduled EndMT generates cancer-associated myofibroblasts that fuel inflammation and fibrosis, and may contribute to vascular dysfunction that promotes tumor progression. We report that freshly isolated subpopulations of tumor-specific endothelial cells (TEC) from a spontaneous mammary tumor model undergo distinct forms of EndMT in response to TGFb stimulation. Although some TECs strikingly upregulate a smooth muscle actin (SMA), a principal marker of EndMT and activated myofibroblasts, counterpart normal mammary gland endothelial cells (NEC) showed little change in SMA expression after TGFb treatment. Compared with NECs, SMA þ TECs were 40% less motile in wound-healing assays and formed more stable vascular-like networks in vitro when challenged with TGFb. Line-age tracing using ZsGreen Cdh5-Cre reporter mice confirmed that only a fraction of vessels in breast tumors contain SMA þ TECs, suggesting that not all endothelial cells (EC) respond identically to TGFb in vivo. Indeed, examination of 84 TGFb-regulated target genes revealed entirely different genetic signatures in TGFb-stimulated NEC and TEC cultures. Finally, we found that basic FGF (bFGF) exerts potent inhibitory effects on many TGFb-regulated genes but operates in tandem with TGFb to upregulate others. ECs challenged with TGFb secrete bFGF, which blocks SMA expression in secondary cultures, suggesting a cell-autonomous or lateralinhibitory mechanism for impeding mesenchymal differentiation. Together, our results suggest that TGFb-driven EndMT produces a spectrum of EC phenotypes with different functions that could underlie the plasticity and heterogeneity of the tumor vasculature. Cancer Res; 75(7); 1-11. Ó2015 AACR.
Introduction
Endothelial-to-mesenchymal transition (EndMT) is defined as the loss of endothelial-specific factors and gain of mesenchymal features that accompany the morphogenesis of specific tissues, especially those of the heart (1). EndMT also occurs in various pathologic conditions, including cerebral cavernous malformations, cardiac and kidney fibrosis, vein stenosis, and cancer (2) (3) (4) (5) (6) (7) . In these diseased states, aberrantly regulated EndMT results in unscheduled conversion of endothelial cells (EC) into diverse mesenchymal-lineage cell types, especially myofibroblasts, that may dissociate from the vessel wall and can be found throughout the affected tissue (8) (9) (10) (11) (12) (13) (14) . EndMT coincides with genome-wide reprogramming that allows ECs to exist in a variety of phenotypic states but may also cause vascular dysfunction that contributes to disease progression (9, 15, 16) .
The concept that ECs may "drift" toward mesenchymal-like cell types was shown many years ago in TGFb-treated EC cultures (17) . TGFb, and other members of the TGFb superfamily, impart plasticity to ECs by activation of specific transcription factors (e.g., Snail, Slug, and Twist) that interact with chromatin modifiers to create genome-wide epigenetic reconfigurations (15, 18) . Whether acquisition of the mesenchymal program in EC is a partial and transient or stable and transmittable change in cellular specification is not clear. The context dependency of TGFb, combined with its cell-type specific activity, has made it challenging to understand how ECs react to sustained TGFb signaling, particularly in complex tissues such as tumors (19, 20) . In addition, EC cellular responses to TGFb may proceed differently in different types of EC owing to heterogeneous forms of mesenchymal differentiation throughout the vasculature that is tumor-type and/or tumor-stage dependent.
Recently, we isolated normal mammary gland ECs (NEC) and mammary tumor ECs (TEC) from a transgenic tumor model (21) . We were surprised to find a wide range of mesenchymal-like genetic signatures among these different types of ECs challenged with TGFb in vitro. Furthermore, although some TGFb-stimulated mesenchymal genes (e.g., smooth muscle actin a; SMA) were blocked by addition of basic FGF (bFGF), expression of other mesenchymal genes was augmented by the combination. These results require a refined assessment for how EndMT is defined across different vascular beds. In principle, EndMT may be characterized by a spectrum of intermediate and reversible mesenchymal-cell phenotypes, especially in pathologic tissues. Moreover, ECs resist specific conversion to SMA þ myofibroblast-like cells when challenged with TGFb through secretion of bFGF; thus, ECs maintain their own fate and differentiation by a self-regulatory mechanism that counteracts TGFb activity.
Materials and Methods

EC isolation, cell culture, and media
Mammary NECs and TECs were isolated from C3-TAg (FVB/N C3 1 -TAg) mice and FVB wild-type mice, respectively (21) . We previously isolated prostate TECs from TRAMP mice (8) , and K-Ras lung TECs were isolated from K-RasG12D mouse lung tumors (22) . Fluorescently labeled acetylated low-density lipoprotein (DiI-Ac-LDL; Biomedical Technologies) was incubated with lung TEC clones to examine cell purity under a fluorescent microscope (23) . EC clones were maintained in 1 g/L D-glucose DMEM (LG-DMEM, Gibco) supplemented with 10% FBS, 10% Nu-Serum IV (BD), 5 ng/mL bFGF (Peprotech), 10 ng/mL VEGF A (Peprotech), and 20 USP U/mL heparin (Sigma). Mouse mesenchymal stem cells (MSC) were purchased from Gibco and were maintained in DMEM/F-12 (Gibco) with 10% MSC-qualified FBS (Gibco). All media were supplemented with antibiotic-antimycotic (Gibco).
Unless otherwise stated, 5 ng/mL bFGF and/or 10 ng/mL TGFb2 in 20% FBS or 1% FBS LG-DMEM was used to treat cells for 48 hours before protein or RNA extraction. BMP-2 (Peprotech), BMP-6 (Peprotech), and BMP-7 (Peprotech) were used at 100 ng/mL. Small-molecule inhibitors were added to the media for one hour before TGFb2 treatment. The following reagents used were: TGFb2R inhibitor (SB431542, Sigma), PI3K inhibitor LY294002 (Sigma), Akt inhibitor VIII (EMD Millipore), Smad3 inhibitor SIS3 (Calbiochem), mTOR inhibitor rapamycin (Sigma), MEK (MAPK/ERK kinase) 1/2 inhibitor U0126 (Calbiochem), bFGF neutralizing antibody (Millipore, 05-117), and FGF receptor (FGFR) kinase inhibitor (Calbiochem).
Real-time qPCR
Total RNA isolation was completed using an RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions, and cDNA synthesis was carried out using an iScript cDNA Synthesis Kit (Bio-Rad). qPCR was run in triplicate in 10 mL/reaction with 2Â Maxima SYBR Green (ThermoFisher) on an Applied Biosystems
Step One Plus analyzer. The threshold cycle (C t ) values were determined by Step One Software 2.2.2 by Applied Biosystems. C t values of Gapdh gene expression were used as an endogenous control. The relative expression of each gene was quantified using the formula: 2e (Ct of Gapdh À Ct of gene X) ¼ fold increase of reference gene expression. Primer sequences are available upon request. Heatmaps were generated using Gene-E (http://www.broadinstitute.org/cancer/software/GENE-E/.)
Western blot analysis
Cells were lysed in RIPA buffer complemented with phosphatase and protease inhibitor cocktails (Sigma) for protein extraction. Protein concentrations were determined by Bradford assays, and approximately 30 mg per sample was used for Western blotting. For non-phosphorylated protein detection, membranes were blocked and antibodies were added in 5% milk TBS with 0.1% Tween 20 (TBST), and for phosphorylated protein detection, 5% BSA TBST was used. Membranes were incubated with primary antibodies at 4 C overnight and then with secondary antibody at room temperature for one hour. Primary antibodies: 1:1,000 mouse anti-SMA (Sigma, A5228), 1:1000 rabbit antiphospho-Ser 465/467 SMAD2 (pSMAD2; Cell Signaling Technology, 3108), 1:1,000 rabbit anti-phospho-Ser 423/425 SMAD3 (pSMAD3; Millipore, 0713-89), 1:1,000 rabbit anti-SMAD2 (Cell Signaling Technology, 5339), 1:1,000 rabbit anti-SMAD2/3 (Cell Signaling Technology, 8685), 1:1,000 rabbit anti-fibronectin (Abcam, ab2413), 1:1,000 rabbit anti-bFGF (Sigma), 1:1,000 rabbit anti-phospho-Thr 202/204 ERK (pERK) 1/2 (Cell Signaling Technology, 4370), 1:2,000 rabbit anti-ERK1/2 (Cell Signaling Technology, 9102), 1:1,000 rabbit anti-VEGF receptor 2 (VEGFR2; Cell Signaling Technology, 55B11), and 1:2,500 rabbit anti-GAPDH (Cell Signaling Technology, 5174). Secondary HRPconjugated antibodies: 1:10,000 horse anti-mouse and 1:10,000 goat anti-rabbit antibodies (Vector Laboratories).
Wound closure scratch assay and live imaging
Cells were plated at 1.0 Â 10 5 cells/well in 6-well plates. Twenty-four hours later, the monolayer was gently scratched with a 200 mL pipette tip across the center of the well. An Olympus IX70 Inverted Live Cell System was used for time-lapse imaging of the cells at a minimum of four locations/well at 20-minute intervals until the scratch wound was completely closed. The images were acquired with the Volocity 6.2 software package (PerkinElmer) and analyzed using TScratch software (available at: http://www. cse-lab.ethz.ch) according to the developers' instructions. (24) . The open areas on the images were quantified with the software's automated image analysis and expressed as relative area closure with an arbitrary area unit assigned by the software. Phase contrast images were captured with a Hamamatsu ORCAR2 camera.
Matrigel tube formation assay
Growth factor-reduced Matrigel (Corning, 356230) was first plated into 96-well plates and allowed to set for 30 minutes at 37 C. Cells were preincubated in 10% FBS medium with or without TGFb2 for 16 hours before being detached and plated in 10% FBS medium with or without TGFb2 in Matrigel-containing wells in triplicate at a density of 1.0 Â 10 4 cells/well. Phase contrast images (4Â) were taken on an Evos XL Core Cell Imaging System (Life Technologies) at approximately 7 hours. Images were processed with ImageJ using the "find edges" feature to enhance the contrast. Quantification was done by counting vessel-like cords that were formed by at least two nonadjacent cells. A 3 Â 3 grid was superimposed on each image, and at least four random squares were counted per image to obtain an average number of tubes per image.
Flow cytometry
Flow cytometry was performed using a BD Accuri C6 Flow Cytometer as previously described with data analyzed post hoc using FloJo (version X; ref. 21) . Antibodies: PE rat anti-mouse CD31 (BD Pharmingen, 553373), PE rat anti-mouse CDH5 (VEcadherin; BD Pharmingen, 562243), and rat anti-mouse IgG (BD Pharmingen, 55393) at a ratio of 1.5 mL antibody to 100 mL of cell suspension.
Tumor studies in mice C3-TAg mice were provided by the Mouse Phase 1 Unit from the Lineberger Comprehensive Cancer Center at University of North Carolina (UNC) Chapel Hill (Chapel Hill, NC). Tumors were harvested when mice were approximately 5 months of age. ZsGreen Cdh5-Cre mice were generated by crossing R26 ZsGreen mice (Jackson Laboratory, 007906) and Cdh5-Cre mice (Jackson Laboratory, 006137). E0771 murine mammary tumor cells (CH3 BioSystems, 940001) or PyVMT tumor cells isolated from the PyVMT mice were suspended in Matrigel (Corning, 356234) at a density of 1.0 Â 10 7 cells/mL, and 100 mL of cell suspension was orthotopically injected into the mammary fat pats of 7-week-old female ZsGreen Cdh5-Cre mice (25) . Tumors were harvested when they reached 1 cm 3 in size, and normal mammary glands from age-matched littermates were harvested at the same time. Lung tumors were obtained from K-RasG12D mice (22) . Tissues were fixed in 4% paraformaldehyde and cryoprotected in 30% sucrose-PBS before OCT embedment and cryosection. All mouse experiments were carried out under approval of the Institutional Animal Care and Use Committee at UNC-Chapel Hill.
Immunofluorescence
Immunofluorescence methods were described previously (8) . Antibodies used were: 1:100 rat anti-mouse CD31 antibody (BD, 550274), 1:200 Alexa Fluor 488 goat anti-rat antibody (Invitrogen, A11006), and 1:500 monoclonal mouse anti-a-SMA Cy3 antibody (Sigma, C6198). Slides were mounted with Vectashield Hardset Mounting Medium with DAPI (Vector Laboratories) and imaged on a Zeiss CLSM 710 or 700 Spectral Confocal Laser Scanning Microscope.
Three-dimensional confocal microscopy
Sections were stained as described above, and imaged on a Zeiss CLSM 710 Spectral Confocal Laser Scanning Microscope using cubic voxels to capture the z-dimension. Three-dimensional projections, orthogonal slices, and the Supplementary Movie (Movie S1) were generated using ImageJ (http://imagej.nih.gov/ij/).
TGFb pathway qPCR array
The array was carried out in duplicate using the Mouse TGFb Signaling Targets RT 2 Profiler PCR Array (SA Biosciences, PAMM-235Z) according to the manufacturer's instructions. Cells were plated and exposed to TGFb2 and/or bFGF for 48 hours. Total RNA was purified with an RNeasy Mini Kit (Qiagen) and cDNA synthesis was performed with an iScript cDNA Synthesis Kit (Bio-Rad). ABI 7900HT Quantitative PCR System was used for the qPCR array and the data were analyzed with SA Biosciences' RT 2 Profiler PCR Array Data Analysis Online Software.
Conditioned media treatment of TEC-H8
Conditioned media (CM) collected from TEC-H8 treated with or without TGFb2 (10 ng/mL) for 48 hours were concentrated using Amicon Ultra-15 Centrifugal Filter Unit (Millipore) or Pierce Protein Concentrators (Thermo Scientific). For Western blot analysis of bFGF, 25 mL of the concentrated CM was used, and the remaining concentrated CM were then divided equally to treat a new batch of TEC-H8 for 48 hours in the presence or absence of freshly added TGFb2. Cell lysates were collected for Western blot and qPCR analyses.
Statistical analysis
All values are expressed as AE SEM. Results were analyzed by a Student t test or ANOVA using GraphPad Prism 5 software. P values less than 0.05 were considered significant.
Results and Discussion
Isolation of TECs with an intermediate EndMT phenotype
We recently isolated multiple NEC and TEC clones from wildtype mice and spontaneous mammary tumors in C3-TAg mice using a high-fidelity cloning method producing pure EC populations uniformly positive for CD31 and CDH5 ( Fig. 1A and B ; ref. 21) . Surprisingly, a number of TEC clones showed elevated basal mRNA expression of the EndMT and myofibroblast differentiation marker, SMA (Acta2; Fig. 1C ). On the other hand, expression of endothelial markers Cd31 and Vegfr-2 were variable among all NEC and TEC clones and did not correlate with the levels of Acta2 mRNA (Fig. 1C ). When challenged with TGFb2, TEC-H8 (a clone with high basal SMA expression) upregulated SMA protein expression, whereas an NEC clone (B12) and TEC-A2 (a SMA-low TEC clone) were relatively unresponsive ( Fig. 2A ). TEC-H8 were responsive to all three TGFb isoforms and similar results were obtained using an additional mammary TEC clone with high SMA mRNA (TEC-D8) and mesenchymal-like prostate TECs previously described by us ( Fig. 2B and C; ref. 8). As non-EC (e.g., SMA þ fibroblast) contamination can occur during EC isolation, we performed staining with SMA and CD31 to exclude this possibility. All individual cells in the TEC clone examined expressed CD31, and confocal images clearly revealed colocalization of SMA þ stress fibers and CD31 in the same cells post-TGFb2 treatment (Fig. 2D ). SMA þ ECs have been observed in the luminal surface of healthy thoracic aorta, but their density is markedly increased in atheromatous aorta (26) . The appearance of SMA þ ECs correlates with a proinflammatory state, such as in tumors or fibrosis, where TGFb is also highly upregulated (27, 28) . It is possible that the tumor microenvironment promotes the conversion of SMA À ECs into SMA þ ECs, or favors the enrichment of rare but preexisting SMA þ EC located throughout the mammary gland vasculature.
To test whether there were any functional differences between SMA-high TECs and NECs, we carried out a time-lapse wound-healing migration assay using TEC-H8 and NEC-B12 clones. NEC-B12 challenged with TGFb2 showed little difference in migration compared with untreated controls, whereas TEC-H8 migration was inhibited by approximately 40% (Fig. 3A ). TGFb2 also markedly enhanced TEC-H8 contraction in collagen gel contraction assays, while exerting little effect on NEC-B12 (D.J. Kim; unpublished data). These results are consistent with previous studies showing impaired migration of SMA þ myofibroblasts and are perhaps related to higher contractility and increased focal adhesions associated with filamentous actin stress fibers (29) (30) (31) . In contrast, formation of in vitro vascular structures was inhibited by 60% to 80% in NEC-B12 and SMAlow TECs (TEC-A2) challenged with TGFb2 but were increased by 40% in TEC-H8 ( Fig. 3B ). Taken together, our data suggest that subpopulations of EC are differentially receptive to TGFb stimulation: some are characterized by high SMA induction, decreased migration, and stabilized vascular structures, whereas others respond oppositely.
TGFb induces diverse genetic signatures in different types of ECs
We next used qPCR to compare the expression pattern of 12 mesenchymal marker genes in TGFb2-treated NEC-B12 versus TEC-H8 cultures. Strikingly, we found the pattern of gene expression to be entirely opposite when these genes were hierarchically clustered ( Fig. 4A ). For example, although NEC-B12 strongly upregulated mesenchymal markers, including calponin 1 (Cnn1), transgelin (Tagln), cadherin 11 (Cdh11), and endosialin (Cd248), TEC-H8 strongly increased the expression of Acta2 (SMA), fibronectin 1 (Fn1), platelet-derived growth factor (PDGF) receptor b (Pdgfrb), and desmin (Des). Basal FN1 protein expression was also slightly higher in TEC-H8 and was further increased after TGFb2 stimulation as shown by Western blotting ( Supplementary Fig. S1A ). Another cluster of mesenchymal genes, including tenascin c (Tnc), endoglin (Eng), and vimentin (Vim), were slightly elevated in TEC-H8 and their levels were variably altered by TGFb2 treatment. The EC markers Cdh5, Cd31, and Vegfr1 were either moderately decreased or unchanged by TGFb2 challenge. Longer periods of TGFb2 treatment could result in sustained downregulation of these and other EC-specific genes. Notably, the pericyte marker Ng2 was not detected in NECs or TEC-H8 with or without TGFb2 treatment, ruling out the presence of contaminating pericytes in these cultures (data not shown).
Because both SMAD-dependent and SMAD-independent pathways are implicated in mesenchymal gene regulation during EndMT, we used pharmacologic inhibitors to evaluate different mechanisms of TGFb2-induced SMA expression in TECs (32) . We found that TGFb regulated SMA expression in TECs via PI3K, Akt, and SMAD3, but not through mTOR (Fig. 4B ). To determine whether differential expression of SMADs could account for the divergent responses to TGFb2 in NEC versus TEC cultures, we assessed levels of pSMAD2 and pSMAD3 using Western blotting. We found similar basal pSMAD2 and pSMAD3 levels in both NEC-B12 and TEC-H8 cultures ( Supplementary Fig. S1B and S1C). TGFb2 further induced SMAD2 and SMAD3 phosphorylation in the two cell types to a similar level, with comparable total SMAD2/3 expression, indicating that TGFb2 signaling is not altered in TEC-H8 compared with NEC-B12. However, TGFb2activated SMADs regulate distinct groups of target genes in NECs versus TECs, suggesting that either additional cofactors are differentially recruited to mesenchymal gene promoters in the two cell types or that a different set of mesenchymal genes may be poised for transcription in different types of ECs.
Only a fraction of tumor vessels contain SMA þ ECs in vivo
We found that primary EC clones displayed a spectrum of SMA expression upon TGFb2 stimulation, suggesting that not all ECs respond identically to TGFb2 challenge. To test this possibility in vivo, we fate-mapped tumor endothelium using ZsGreen Cdh5-Cre reporter mice to indelibly mark all ECs ( Supplementary Fig. S2A  and S2B ). Three-dimensional confocal imaging of these tumors at high magnification clearly demonstrated that SMA and ZsGreen localized in the same cells ( Supplementary Figs. S2C and S3 and Supplementary Movie S1). Consistent with our in vitro findings, we observed that in two different orthotopically implanted mammary tumors, only a minor fraction ($1%-10%) of tumor blood vessels contained SMA þ ECs, whereas few if any SMA þ ECs were found in normal mammary glands (Fig. 4C ). On the other hand, blood vessels in spontaneous C3-TAg mammary tumors and K-RasG12D lung tumors showed a broad range (0%-25%) of CD31 and SMA coexpression in ECs (Fig. 4D) . The higher frequency of CD31 þ /SMA þ ECs in these genetically engineered mouse (GEM) models could be due to the longer tumor growth period, or in the case of lung, be related to underlying plasticity inherent within the vascular bed (i.e., different vascular beds show differential proclivity to undergo EndMT). However, it is challenging to discriminate between SMA þ pericytes and the closely underlying CD31 þ ECs using immunostaining in these models and these results must be interpreted with caution; therefore, the frequency of CD31 þ /SMA þ ECs in these GEM models could be overestimated.
These results suggest that ECs variably acquire SMA expression in the tumor models we evaluated, but SMA þ ECs may be more common in other tumor types; for example, in pancreatic tumors where fibrosis is a prominent feature and the percentages reported are markedly higher ($40%; ref. 5). SMA þ ECs might appear only transiently during different stages of tumor progression, or are generated continuously, but can revert to SMA À ECs, depending on the balance of EndMT promoting (or inhibiting) factors present in the tumor microenvironment. Though ZsGreen Cdh5-Cre mice are a high-fidelity EC lineage-tracing model, it is also conceptually possible that SMA þ fibroblasts or other mesenchymal-lineage cells may acquire EC markers through mesenchymalto-endothelial transition (MEndT), which is a reverse process of EndMT. Although EndMT has been observed in a wide range of conditions, the phenomenon of MEndT in tumors is still a matter of debate (33) . In contrast with EndMT, which may arise spontaneously in vitro, generation of ECs from lineage-committed mesenchymal cells requires enforced induction of multiple ECselective transcription factors in addition to TGFb inhibition, indicating that MEndT demands restrictive conditions and precise temporal activation of specific regulatory factors (34) . Therefore, SMA þ ECs in our model are more likely to be originated from endothelial-lineage cells via EndMT rather than mesenchymallineage cells through MEndT.
bFGF opposes the expression of some TGFb target genes but augments the expression of others Similar to epithelial-to-mesenchymal transition (EMT), we expected that conversion of ECs to mesenchymal-like cells was dynamic and could be reversed upon removal of TGFb2 from the culture medium. Indeed, we found that when TGFb2 was removed and cells were returned to their normal growth medium, which contains bFGF (EC media), SMA expression was rapidly lost and TECs regained their typical EC morphology ( Supplementary Fig. S4A and S4B) . The same cell population upregulated SMA again after being returned to TGFb2containing media, indicating that some TECs may readily morph between SMA À endothelial and SMA þ mesenchymallike phenotypes. We further determined that bFGF, but not Figure 3 . A, a, wound closure rates of NEC-B12 and TEC-H8 treated with or without TGFb2. b, representative images of the wound closure at indicated time points. White dotted lines, migration fronts of cells. Cells were exposed to 10 ng/mL TGFb2 in 20% FBS LG-DMEM for approximately 30 minutes before imaging (n ¼ 3). Scale bar, 100 mm. Statistical significance was determined by two-way ANOVA ( ÃÃ , P < 0.001). B, representative phase-contrast images of Matrigel tube formation of NECs (a and b), TEC-G8 (c and d), and TEC-H8 (e and f) with or without TGFb2 treatment. g, quantification of tubes by counting the number of tubes per field. Scale bar, 1 mm; 3-4 observations. Statistical significance was determined using a Student t test ( Ã , P < 0.05).
VEGF, suppressed TGFb2-induced SMA expression ( Fig. 5A ). Similar to interstitial cells in the heart, bFGF neutralized TGFb2-stimulated SMA expression in TECs at 500 pg/mL, a concentration that was 20-fold lower than the TGFb2 concentration added to the culture medium ( Fig. 5B; ref. 35 ). Remarkably, acidic FGF (aFGF), the closely related isoform of bFGF, did not neutralize SMA expression in TGFb2-challenged cells at the same concentrations. Suppression of TGFb2-induced SMA expression by bFGF was confirmed at the protein level by immunofluorescence (Fig. 5C ). Simply removing bFGF from the culture medium promoted TECs to drift toward a mesen-chymal-like phenotype indicated by a moderate increase in SMA expression, especially in cells maintained at subconfluent conditions ( Supplementary Fig. S4C ). Moreover, these subconfluent cells were highly receptive to TGFb stimulation compared with confluent cultures and showed robust SMA induction and more pronounced VEGFR2 suppression (Supplementary Fig. S4C ), indicating that loss of cell-cell contact enhances TGFb responses. Thus, bFGF functions both as a potent EC mitogen and a "specification factor" that prevents ECs drift toward mesenchymal-like cell types, particularly in the presence of TGFb. Next, we carried out a TGFb2 pathway qPCR array to comprehensively assess the expression of 84 TGFb2 target genes in NEC versus TEC cultures, either with or without addition of bFGF. The results showed that, as predicted, TGFb2 induced distinct expression patterns in NEC versus TEC cultures (Fig. 5D ). Furthermore, although bFGF counteracted TGFb2-induced expression of the mesenchymal genes Acta2 and thrombospondin 1 (Thbs1), TGFb2 and bFGF synergistically activated other genes such as Notch1 and S100a8, which were shown previously to regulate tumor angiogenesis ( Fig. 5D; refs. 36, 37 ). Although repressing SMA, bFGF rescued the expression of Vegfr-2, which was suppressed by TGFb2 challenge; however, bFGF only marginally downregulated expression of the transcription factor Snail, which was previously identified as a master regulator of EndMT (Supplementary Fig. S4D; ref. 38 ). Interestingly, bFGF expression was increased by TGFb2 stimulation, suggesting a possible autocrine or paracrine feedback loop in ECs to counteract TGFb2-induced expression of specific target genes, namely SMA ( Supplementary  Fig. S4D ).
To further confirm the protective role of bFGF in neutralizing TGFb-induced SMA expression, we examined gene expression patterns in an additional C3-TAg TEC clone with relatively low basal SMA mRNA (TEC-G8). bFGF completely suppressed TGFb-induced SMA expression in TEC-G8, even though the SMA levels were significantly lower than those in the SMA þ clone TEC-H8 ( Supplementary Fig. S5A and S5B) . To assess the interaction between bFGF and TGFb in ECs derived from a different tumor model, we isolated lung TECs from K-RasG12D mouse lung tumors (22) . All clones were virtually 100% positive for DiI-Ac-LDL uptake and CD31, and strongly expressed VEGFR2 (Supplementary Fig. S6A and S6B) . Interestingly, unlike C3-TAg TEC clones, the K-Ras TEC clones showed elevated basal SMA protein that was detectable by Western blotting even in EC media that contained bFGF, suggestive of a "partial" EndMT phenotype in EC subpopulations derived from lung. The expression of SMA and other myofibroblast markers, including Col1a1, Fn1, and Tagln, in these K-Ras clones was further stimulated by TGFb2 in the absence of bFGF, although to a lesser extent when compared with SMA þ mammary TECs ( Supplementary Fig. S6B and S6C ). Addition of bFGF variably antagonized the effect of TGFb on these genes, indicating that bFGF may act through similar pathways in different types of ECs to maintain EC fate ( Supplementary Fig. S6C ). Although Twist1 and Twist2 have been implicated in the induction of mesenchymal genes during EndMT and EMT; surprisingly, we did not observe an upregulation of Twist1 or Twist2 by TGFb (39) . It is possible that induction of these genes in ECs requires Profiler PCR Array. Cells were stimulated for 48 hours with TGFb2 and/or bFGF as indicated, and the arrays were performed in duplicate.
Results were normalized and log transformed, and genes were clustered using the Pearson correlation.
prolonged stimulation with TGFb or they play only a marginal role during EndMT. Previous studies have demonstrated that bFGF can antagonize TGFb through the MAPK/ERK kinase pathway to suppress fibrogenic effects in epithelial cells and revert EMT, a process closely related to EndMT (40) . Providing a further link between bFGF and TGFb signaling, basal SMAD2 phosphorylation and TGFbR1 levels are increased when FRS2, an FGFR coactivator, is depleted using shRNA (41) . In lymphatic ECs, bFGF was reported to suppress TGFb-stimulated SMAD2 activation via MAPK signaling (42) . However, we found that although bFGF strongly induced EKR1/2 activation, it exerted no observable effects on TGFb2stimulated SMAD2 phosphorylation and only weakly reduced SMAD3 phosphorylation after a 60-minute TGFb2 stimulation ( Supplementary Fig. S7A ). Furthermore, inhibition of MAPK/ERK only mildly disabled the opposing effect of bFGF on TGFbinduced SMA ( Supplementary Fig. S7B ), indicating that bFGF may counteract TGFb signaling through additional mechanisms.
Bone morphogenetic proteins (BMP), which are members of the TGFb superfamily, can interact synergistically or antagonistically with TGFb to fine-tune cellular differentiation. For example, BMP-2 controls cardiac valve formation through Snail1-mediated EMT during heart development, whereas BMP-7 was reported to attenuate TGFb-induced EndMT in cardiac fibrosis (4, 43) . In addition, BMP-6 acts as a major inhibitor of renal fibrosis as loss of BMP-6 increases SMA and FN1 expression in obstructed kidneys (44) . However, we found that treatment with BMP-2, 6, or 7 did not overly affect SMA or FN1 expression stimulated by TGFb2 in ECs ( Supplementary Fig. S7C ), suggesting that interaction between TGFb and BMP signaling may be cell-type dependent. ECs challenged with TGFb secrete their own bFGF, which suppresses mesenchymal-like differentiation in secondary cultures. A, dose-and time-dependent induction of bFGF mRNA expression in TEC-H8 challenged with TGFb2. In the dose-response experiment, cells were treated with increasing concentrations of TGFb2 for 48 hours, and in the time-dependent experiment, cells were stimulated with 10 ng/mL TGFb2. B, Western blot analyses showing secreted and intracellular bFGF in TEC-H8 challenged with 10 ng/mL TGFb2 for the indicated times. Ponceau staining (PS) and GAPDH were used as loading controls for secreted proteins and cell lysates, respectively. Arrowheads, bFGF isoforms of different molecular weights. C, secondary TEC-H8 culture treatments with CM obtained from TEC-H8 challenged with TGFb2. a, schematic diagram of the CM experiment. Media conditioned by TEC-H8 stimulated with or without TGFb2, and media containing only TGFb2 were concentrated and used to treat secondary TEC-H8 cultures for 48 hours. b, Western blot analysis of SMA expression in the secondary TEC cultures treated with CM or cell-free media, and Western analysis of secreted bFGF in the CM and cell-free media. c, qPCR analysis of changes in mRNA expression in secondary TEC-H8 cultures treated with CM or cell-free media. d, qPCR analysis of Acta2 (SMA) mRNA expression in TEC-H8 treated with increasing doses of either a bFGF-blocking antibody (BA) or a FGFR kinase inhibitor (KI) in the presence of 10 ng/mL TGFb2 for 48 hours. From left to right, the bFGF BA concentrations are 0 mg/mL, 20 mg/mL, 0 mg/mL, 10 mg/mL, 15 mg/mL, and 20 mg/mL, and the FGFR KI concentrations are 0 nmol/L, 200 nmol/L, 0 nmol/L, 40 nmol/L, 120 nmol/L, and 200 nmol/L. Graphs are representative of three independent experiments. Error bars, SEM (n ¼ 3). Significance was determined using a one-way ANOVA and is indicated by an asterisk (P < 0.05).
More specifically, different types of ECs may respond differently to combinations of TGFb and BMP signals. Taken together, our results suggest that EndMT, while sharing many features with EMT, is a distinctly regulated process that is variably regulated in different vascular beds, or in different disease settings.
ECs challenged with TGFb secrete their own bFGF, which suppresses mesenchymal-like differentiation in secondary cultures
Because bFGF potently blocks TGFb-stimulated conversion to SMA þ mesenchymal cells, and ECs upregulate bFGF in response to TGFb, we asked whether a cell autonomous mechanism in ECs could counteract TGFb challenge. Consistent with our findings, a recent study using microarrays also showed that ECs challenged with TGFb upregulate bFGF mRNA (2) . First, we confirmed that TGFb2 dose dependently increased bFGF mRNA expression, with a maximum approximately 10-fold increase after 10 ng/mL TGFb2 treatment (Fig. 6A ). TGFb2 also time dependently increased bFGF expression, with maximum levels peaking at approximately 10-fold above untreated control cells after 48 hours. Next, we harvested the CM and cellular lysates of TGFb2-challenged TECs. We found a striking time-dependent increase in bFGF secretion and a slight increase in bFGF expression in the cellular lysates after TGFb2 stimulation (Fig.  6B) . Notably, we observed that secreted bFGF migrated at three different molecular weights, which is consistent with a previous study reporting multiple splice variants of bFGF (45) .
To determine whether EC-derived bFGF could oppose TGFb2 activity, we challenged TEC cultures with TGFb2 and then harvested the CM to rechallenge secondary cultures (Fig. 6C, a) . We found that CM collected from TECs stimulated with TGFb2 induced approximately 2-fold less SMA expression in secondary cultures treated with cell-free media containing equal amounts of TGFb2 (Fig. 6C, b and c) . The decrease in SMA expression in secondary cultures correlated with the presence of secreted bFGF protein in the CM. qPCR analysis of additional mesenchymal and EC genes, including Tagln, Pdgfa, Thbsp1, Cd31, and Cdh5, further showed that the CM of TGFb2-challenged primary cultures could oppose the effects of TGFb2 in secondary cultures. In contrast, S1008a, which can be induced synergistically by TGFb2 and bFGF as revealed by the TGFb pathway array (refer to Fig. 5D ), showed a similar expression pattern after the CM treatment, whereas the expression of Snail was not affected. To test whether the TGFb2antagonizing effect of the CM was specifically due to an increased bFGF production by TECs, we used a bFGF-blocking antibody (BA) and an FGFR kinase inhibitor (KI) to neutralize bFGF activity. As expected, blocking bFGF signaling by either compound increased TGFb2-stimulated SMA mRNA expression in TECs (Fig. 6C, d) . However, neutralizing bFGF with a BA or KI only had a modest effect on SMA expression, possibly because SMA mRNA levels were already maximized by the addition of TGFb2.
Our results have shown that ECs exhibit heterogeneity in their responses to TGFb: some express high-basal SMA and react to TGFb by generating SMA þ myofibroblast-like cells with distinct functions, whereas others have low-basal SMA and transition to SMA À fibroblast-like cells (Fig. 7) . These results are remarkably similar to what has been reported for epithelial cells and suggest parallels between the processes of EMT and EndMT (46) . However, ECs that have undergone a partial mesenchymal-like transition may be directed to a stable SMA þ mesenchymal-like phe-notype, perhaps after prolonged TGFb stimulation or disruption in bFGF signaling (41) . In addition to regulation by growth factors and cytokines, EndMT may also be controlled by epigenetic barriers within the different subpopulations of ECs that guide them toward one lineage or the other. These epigenetic restrictions could explain heterogeneity in EC responses to TGFb signaling. EC markedly increases bFGF production in response to stimulation by TGFb2; thus, one EC that receives TGFb could protect neighboring ECs from mesenchymal-like differentiation through a lateral inhibitory mechanism involving bFGF secretion (47) . A similar mechanism of lateral inhibition involving VEGF/Notch signaling is well known in ECs, as it occurs during fate determination of tip cells during sprouting angiogenesis (48) . In tumors, organ fibrosis, and other chronic inflammatory conditions, the extent of EndMT will likely be determined by local concentrations of several interacting cytokines and growth factors, including TGFb, bFGF, and BMPs, and perhaps on organ-specific properties and heterogeneity of the ECs that form the microvasculature (49) . Notably, in endoglin-(a TGFb2 co-receptor) deficient mice, EndMT in tumor vessels was exacerbated and the frequency of metastases was increased (13) . On the other hand, endoglin deficiency delayed resistance to an antiangiogenic therapy targeting VEGF. These findings bring to light the importance of further understanding the molecular mechanisms that promote and inhibit EndMT in tumors and in other pathologic conditions.
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No potential conflicts of interest were disclosed. whereas others form SMA À intermediate cells. ECs also upregulate bFGF in response to TGFb, providing a mechanism to counteract TGFb, thereby maintaining endothelial specification via an autocrine or paracrine loop. Prolonged TGFb stimulation may force ECs to reach a "point of no return" and enter an irreversible or stable mesenchymal state. ECs at this stage may completely lose endothelial specification, which cannot be rescued by bFGF addition or TGFb removal, and generate either SMA þ or SMA À mesenchymallike cells. It is also possible that there are epigenetic barriers in place among heterogeneous ECs that restrict SMA À mesenchymal-like ECs from becoming SMA þ , but these barriers could be overcome, depending on specific conditions in the tumor microenvironment.
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